Figures & data
Table 1 Preparation of EGCG-loaded solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)
Table 2 Characterization of the hydrodynamic diameter, ζ potential, EE, and LC of the SLN, NLC, EGCG-SLN, and EGCG-NLC formulations
Figure 1 Cryo-scanning electron microscopy images of (A) SLN, (B) EGCG-SLN, (C) NLC, and (D) EGCG-NLC at 20,000× magnification.
![Figure 1 Cryo-scanning electron microscopy images of (A) SLN, (B) EGCG-SLN, (C) NLC, and (D) EGCG-NLC at 20,000× magnification.](/cms/asset/f1749ac7-912c-4098-8537-1038cbb75c76/dddt_a_12166270_f0001_b.jpg)
Figure 2 In vitro EGCG release profiles from SLN and NLC at two different pH values, pH=1.2 (first 4 hours) and 6.5 (from 4 to 24 hours), at body temperature (37°C).
![Figure 2 In vitro EGCG release profiles from SLN and NLC at two different pH values, pH=1.2 (first 4 hours) and 6.5 (from 4 to 24 hours), at body temperature (37°C).](/cms/asset/c1b123e8-b7b3-46aa-9833-1b699c6bab53/dddt_a_12166270_f0002_b.jpg)
Figure 3 MTT results for Caco-2 cell line (mean ± SD) as a function of the different formulations and EGCG concentrations tested (5, 10, 50, 100, and 500 µM), and in the case of placebos the corresponding lipid amount.
Abbreviations: EGCG, epigallocatechin gallate; EGCG-NLC, epigallocatechin gallate loaded nanostructured lipid carriers; EGCG-SLN, epigallocatechin gallate loaded solid lipid nanoparticles; NLC, nanostructured lipid carriers; SD, standard deviation; SLN, solid lipid nanoparticles.
![Figure 3 MTT results for Caco-2 cell line (mean ± SD) as a function of the different formulations and EGCG concentrations tested (5, 10, 50, 100, and 500 µM), and in the case of placebos the corresponding lipid amount.](/cms/asset/857e0ac7-f8c5-498a-9af3-471d7fc5a457/dddt_a_12166270_f0003_b.jpg)
Figure 4 LDH results for Caco-2 cell line (mean ± SD) as a function of the different formulations and EGCG concentrations tested (5, 10, 50, 100, and 500 µM), and in the case of placebos the corresponding lipid amount.
Abbreviations: EGCG, epigallocatechin gallate; EGCG-NLC, epigallocatechin gallate loaded nanostructured lipid carriers; EGCG-SLN, epigallocatechin gallate loaded solid lipid nanoparticles; NLC, nanostructured lipid carriers; SLN, solid lipid nanoparticles.
![Figure 4 LDH results for Caco-2 cell line (mean ± SD) as a function of the different formulations and EGCG concentrations tested (5, 10, 50, 100, and 500 µM), and in the case of placebos the corresponding lipid amount.](/cms/asset/41608c2b-ecb4-48d2-8634-b8c0abd0ada6/dddt_a_12166270_f0004_b.jpg)
Figure 5 Characterization of the hydrodynamic diameter (A), ζ potential (B), and EE (C) during 3 months of storage for SLN, NLC, EGCG-SLN, and EGCG-NLC formulations.
![Figure 5 Characterization of the hydrodynamic diameter (A), ζ potential (B), and EE (C) during 3 months of storage for SLN, NLC, EGCG-SLN, and EGCG-NLC formulations.](/cms/asset/af5ab7de-0903-462b-91f4-0307786b81d5/dddt_a_12166270_f0005_b.jpg)
Table S1 Value of R2 obtained from the release of EGCG from SLN for different models of mechanism of drug release
Table S2 Value of R2 obtained from the release of EGCG from NLC for different models of mechanism of drug release